Sugi Predict

Sugi Predict / Compounds / SCHEMBL4299075

SCHEMBL4299075

SCHEMBL4299075

CC(C)(C)c1cc(NC(=O)Nc2ccc3c(c2)OCO3)n(-c2cccc(CN)c2)n1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 19/20 0.72
▸ MAPK13 O15264 6/20 0.55
▸ MAPK12 P53778 6/20 0.55
▸ MAPK11 Q15759 6/20 0.55
▸ DDR2 Q16832 3/20 0.55
▸ SRC P12931 1/20 0.54
▸ MAPK9 P45984 1/20 0.54
▸ MEN1 O00255 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ RAF1 P04049 1/20 0.52
▸ BRAF P15056 1/20 0.52
▸ EPHB2 P29323 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083662 0.93 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2082979 0.92 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2083034 0.92 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2082310 0.90 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2081660 0.90 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2082943 0.90 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL4302686 0.89 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL4300449 0.88 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL2083212 0.87 MAPK14 (0.57) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL14190095 0.87 MAPK14 (0.57) MAPK14MAPK13MAPK12MAPK11DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 — — EP disclosed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 — — EP disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885MAPK13 183/4885MAPK12 118/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885MAPK13 41/4885MAPK12 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.